Skip to main content

Table 1 Patient age, sex, and cancer prevalence at diagnosis (observed vs. expected)

From: Quantification of cancer risk in glomerulonephritis

 

No. patients

Age (yrs)

Female (%)

Patients with Cancer

Prevalence (%)

Expected prevalence (%)

Risk Ratio

Minimal change

428

43,3 ± 19

46

19

4,4

1.9

2.4 (1.4–3.7) c

Endocapillary

137

43,4 ± 18

53

7

5,1

1.7

3.0 (1.2–6.2) a

Focal segmental glomerulosclerosis

408

49,0 ± 17

34

27

6,6

2.7

2.4 (1.6–3.5) c

Mesangioproliferative

1185

42,2 ± 17

36

36

3,0

1.7

1,8 (1.2–2.5) b

Membranous

741

52,3 ± 17

41

37

5,0

3.2

1.5 (1.1–2.1) a

Membranoproliferative

298

49,2 ± 17

50

22

7,4

2.4

3.1 (1.9–4.7) c

Proliferative

113

43,4 ± 19

46

7

6,2

2.1

2.9 (1.2–6.0) a

Focal segmental proliferative

507

47,3 ± 19

36

15

3,0

2.3

1,3 (0.7–2.1)

Focal

146

56,1 ± 17

41

6

4,1

3.1

1.3 (0.5–1.8)

Crescentic

610

58,4 ± 16

39

27

4,4

3.9

1.1 (0.7–1.6)

Unclassified

552

55,4 ± 18

41

82

14,9

3.0

4.9 (3.9–6.1) c

Anti-GBMGN

92

55,5 ± 22

53

1

1,1

4.4

0.2 (0–1.4)

ANCA associated vasculitis

278

59,1 ± 16

38

21

7,6

4.2

1,8 (1.1–2.5) a

Lupus nephritis unspecified

99

38,1 ± 17

77

1

1,0

1.5

0,7 (0–3.8)

Lupus nephritis all

422

36.4 ± 15

77

7

1.7

0.7

1.2 (0.5–2.5)

Any

5594

49.4 ± 18

41

330

5.5

3.1

1,8 (1.4–2.1) c

  1. Significant risk ratios in bold type
  2. a:< 0.05; b:< 0.01; c:< 0.001